The impact of MUC5AC in the resected samples post-NAT are summarized as follows: (i) EC-45M1 detection post-NAT increased the risk of recurrence; (ii) MM (45M1) expression negatively impacted PFS and OS, but the HRs were not clinically significant; (iii) IM (CLH2) expression had a positive effect on OS; (iv) for the UpS group, MUC5AC expression did not influence the outcomes, but MM (45M1) had a minimal positive effect on PFS in a sub-group that received Gem-based therapy. This evidence concerns the gene MUC5AC and Miyoshi myopathy.